Lipella Pharmaceuticals Inc. (LIPO)
Oxford Ledge is still expanding full research coverage of LIPO. A live quote, fundamentals, and analysis are available in the app; the SEC-sourced material below is what we currently have indexed here.
Business summary
Lipella reformulates generic drugs into new therapeutic candidates for serious diseases with no current approved treatments.
SEC filings
- 8-K 1.03 2026-03-31
- 8-K Departure/election of directors or officers 2026-02-04
- 10-Q Quarterly financial report (unaudited) 2025-11-14
- 8-K Departure/election of directors or officers 2025-10-21
- 8-K Departure/election of directors or officers 2025-10-09
Source: SEC EDGAR.
Insider activity
5 recent insider (SEC Form 4) filings on record for LIPO. View the transactions in the terminal.
Source: SEC EDGAR (Form 4).
- Open LIPO in the Oxford Ledge terminal — live quote, chart, and analysis in the app.
- Browse the covered-stock index
- Learn to analyze stocks yourself
The material above is drawn from public SEC EDGAR filings and is provided for educational purposes, not as investment advice. Live pricing and fundamentals are available in the terminal.